Burkholderia cepaciaHelgi Karl Engilbertsson25. febrar 2004

Burkholderia cepacia skingarSepsisPneumoniaMeningitisCellulitisPeritonitisEndocarditisPericarditisCholangitisSeptic arthritisUrinary tract infections

Medically Important PseudomonadsrRNA homology group I-VGr. I Pseudomonas, 6 tegGr. IIa Burkholderia, a.m.k. 22 tegGr. IIb Ralstonia, 4 tegGr. IIc Oxalobacter, 1 tegGr. IId Pandorae, 4 tegGr. III Comamonas, 2 tegGr. IV Brevundimonas, 2 tegGr. V Stenotrophomonas, 2 teg

MicrobiologyGram-negatfur stafurExtracellulerAerobicNon-fermentiveCatalaseFlagella2-4 circular replicons sta circular chromosomesErfitt a einangraRktun srhfu media

Burkholderia cepacia

Burkholderia cepaciaPseudomonas cepacia var lst fyrst ri 1950 af Walter Burkholder (Cornell University plant pathologist ), sem plntupathogen. Veldur rotnun lauk (latna, cepia)Siar kemur ljs a tkfris human pathogenarnir P. Kingii og P. Multivarans voru smu tegundar.Sustu 10 r komi ljs vi taxonmskar rannsknir stofn baktera, Burkholder cepacia complex

Burkholder cepacia complexMismunandi genotypur me mjg svipaar phenotypurGenomovar I-IXB. cepaciaB. multivoransB. cenocepaciaB. StabilisB. VietnamiensisB. DolosaB. AmbifariaB. AnthinaB. pyrrocinia

Burkholder cepaciaFinnst va:VatniJarvegiDrumMnnumSptalaumhverfiKranavatnInnavlarDialysuvlarStthreinsivkvaIV lausnirCatheterarOg fleira

Burkholderia cepacia skingarTkifrisskillAlgengast hj sjklingum me undirliggjandi sjkdmaCystic fibrosis3,5 % CF sjklinga USA20-30% skinga enda me bacteremiu og dauaChronic granulomatous diseasenmisbldumDMMalignancyHjartabilunCOPD

Burkholderia cepacia pathogenesisVirulence faktorarLyfjanmiAdherance vi plastExoenzymeElastasiGelatinasiAdhesinResistance to nonoxative killing of neutrophilsIntracellular survivalSiderophoresHemolysinExopolysaccharidePiliFlagella

Burkholderia cepacia pathogenesisFinnast helst ndunarvegiColonisering frekar en sking yfirleittSking getur leitt tilNecrotizing pneumoniaBacteremiuEcthyma gangrenosumDICSeptsks shockMultible organ dysfunction syndrome

Ecthyma gangrenosum

Burkholderia cepacia lyfjanmiBeta-laktamasiPenicilln resistanceDihydrofolate reductasiTrimethoprim resistanceAntibiotic efflux pumpChloramphenicol, quinolone og trimethoprim resistanceYtri himnu gegndrpiQuinolone resistanceBreyting bindista lyfja

Burkholderia cepacia meferCystic FibrosisMinocycline 33% nmiMeropenem 28%Chloramphenicol/Minocycline 49%Chloramphenicol/Ceftazidime 26%

Burkholderia cepacia meferBacteremiaCeftazidime (95%)Piperacillin (93%)Minocycline (85%)Cefotaxime (82%)CiprofloxacinImipenemMeropenemQuinolonesTrimethoprimChloramphenicol

MIC = Minimum inhibitory concentrationMIC breakpoints for resistance: Piperacillin 128 g/ml, Ceftazidime 32 g/ml, imipenem 16 g/ml, gentamicin 16 g/ml, minocycline 16 g/ml, Ciprofloxacin 4 g/ml

AntibioticMIC (g/ml)50%MIC (g/ml)90%Resistant isolates (%)Piperacillin8646.1Ceftazidime483.0Imipenem41621.2Gentamicin64>128100Minocycline486.1Ciprofloxacin123.0

Capsule: 90 teg. Antiphagocytic.Adherence: Prtein sem tengjast samgildum tengjum vi prteingrind bakteruveggsins. Tengist gegnum essi prtein sykrungum frumuhimnu hsilsins, ea vitaka platelet activating factor.